Authors

• Leah Davis (ORCID: https://orcid.org/0000-0002-5409-620X)
• Robert Rolleri
• Saakshi Khattri (ORCID: https://orcid.org/0000-0002-5295-8726)
• Ingrid Pansar
• Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
• CC Zouboulis
• Christina Crater
• Wayne Gulliver
• Antonio Martorell
• Thrasyvoulos Tzellos (ORCID: https://orcid.org/0009-0004-5110-4077)
• Koremasa Hayama
• Evangelos J. Giamarellos‐Bourboulis
• Kelsey R. van Straalen
• Afsaneh Alavi
• Brian Kirby
• Christopher J. Sayed

Institutions

• Nihon University (JP)
• University of North Carolina at Chapel Hill (US)
• Mayo Clinic (US)
• National and Kapodistrian University of Athens (GR)
• Nordland Hospital Trust (NO)
• Erasmus MC (NL)
• Städtisches Klinikum Dessau (DE)
• Mount Sinai Hospital (US)
• UCB Pharma (France) (FR)
• St. Vincent's University Hospital (IE)
• Hospital de Manises (ES)
• Newfoundland and Labrador Centre for Applied Health Research (CA)
• Medizinische Hochschule Brandenburg Theodor Fontane (DE)
• Hidradenitis Suppurativa Foundation (US)
• Universitätsklinikum Brandenburg an der Havel (DE)
• UCB Pharma (Belgium) (BE)

Publication Details

Journal

Journal of the European Academy of Dermatology and Venereology

Published

2026-02-14

DOI

https://doi.org/10.1111/jdv.70356

Primary Topic

Hidradenitis Suppurativa and Treatments

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Sanofi
• L'Oreal USA
• Biogen
• Celgene
• CSL Behring
• Regeneron Pharmaceuticals
• Incyte
• XBiotech
• European Commission
• Bundesministerium für Bildung und Forschung
• Eisai
• National and Kapodistrian University of Athens
• Galderma
• Swedish Orphan Biovitrum
• Bausch Health
• Idorsia Pharmaceuticals
• European Academy of Dermatology and Venereology
• InflaRx
• LEO Pharma